Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;7 subunit

Ligand: 4BP-TQS (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
Published in: Proc Natl Acad Sci USA

Ligand: 4OH-GTS-21 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.380000114440918 pKi
Reference (Journal): Docking studies of benzylidene anabaseine interactions with α7 nicotinic acetylcholine receptor (nAChR) and acetylcholine binding proteins (AChBPs): application to the design of related α7 selective ligands.
Published in: Eur J Med Chem

Ligand: A-582941 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
Published in: J Neurosci

Ligand: A-867744 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile.
Published in: J Pharmacol Exp Ther

Ligand: α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin ArIB (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin ImI (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: AQW051 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pKi
Reference (Webpage): MEDI 222:  Identification of AQW051, an alpha7 nicotinic acetylcholine receptor partial agonist for the treatment of cognitive impairment associated with schizophrenia.

Ligand: atracurium (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1983), UK (1999)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
Published in: Anesthesiology

Ligand: AZD0328 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKi
Reference (Journal): Discovery and development of α7 nicotinic acetylcholine receptor modulators.
Published in: J Med Chem

Ligand: BNC375 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity: 5.579999923706055 pEC50
Reference (Journal): Pharmacological Characterization of the Novel and Selective <i>α</i>7 Nicotinic Acetylcholine Receptor-Positive Allosteric Modulator BNC375.
Published in: J Pharmacol Exp Ther

Ligand: BNC375 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity: 5.71999979019165 pEC50
Reference (Journal): Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs.
Published in: ACS Med Chem Lett

Ligand: bradanicline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Published in: Biochem Pharmacol

Ligand: encenicline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.369999885559082 pKi
Reference (Journal): Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Published in: Drugs R D

Ligand: encenicline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.369999885559082 pKi
Reference (Journal): Discovery and development of α7 nicotinic acetylcholine receptor modulators.
Published in: J Med Chem

Ligand: GTS-21 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pKi
Reference (Journal): Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand.
Published in: J Med Chem

Ligand: ivermectin (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Approval source: FDA (1996), UK (2015)
Primary target: no
Median affinity: 5.099999904632568 pEC50
Reference (Journal): Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.
Published in: Mol Pharmacol

Ligand: JNJ1930942 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor.
Published in: J Pharmacol Exp Ther

Ligand: LY2087101 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.
Published in: J Pharmacol Exp Ther

Ligand: mecamylamine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2013)
Primary target: no
Median affinity: 4.809999942779541 pIC50

Ligand: methyllycaconitine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: NS1738 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.
Published in: J Pharmacol Exp Ther

Ligand: NS6740 (Synthetic organic)
Interaction type: Agonist
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.960000038146973 pKi
Reference (Journal): Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
Published in: Br J Pharmacol

Ligand: PHA-543613 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
Published in: J Med Chem

Ligand: PHA-709829 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
Published in: Bioorg Med Chem Lett

Ligand: PNU-120596 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.
Published in: J Neurosci

Ligand: PNU-282987 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.
Published in: J Med Chem